Sub menu

 

 

Updates to the Prescribing Medicines in Pregnancy database - May 2026

Published

The Prescription Medicines in Pregnancy database has now been updated to include the following new entries:

MedicinePregnancy Category
abaloparatideB3
abrocitinibD
atogepantB3
ceftazidime / avibactamB3
belumosudilD
calcifediolB3
cipaglucosidase alfa / miglustatD
crizanlizumabB1
danicopanB3
datopotamab deruxtecanD
deutetrabenazineB3
doravirineB1
efgartigimod alfaC
elafibranorD
etranacogene dezaparvovecB2
fedratinibD
fenfluramineD
foslevodopa / foscarbidopaB3
fruquintinibD
futibatinibD
gilteritinibD
inavolisibD
inebilizumabC
insulin icodecB3
lazertinibD
leniolisibD
letibotulinumtoxinAB3
linaclotideB3
linzagolixD
lumasiranB1
luspaterceptD
marstacimabD
mavacamtenD
nemolizumabB1
odevixibatD
palopegteriparatideB3
pegunigalsidase alfaB3
respiratory syncytial virus (RSV) F protein mRNAB1
ritlecitinibD
rozanolixizumabD
sipavibartB2
sodium iodide [131I]X
sotaterceptD
spesolimabB1
talazoparibD
talquetamabC
tebentafuspC
teprotumumabX
tezepelumabB1
tirbanibulinD
toripalimabD
tremelimumabD
triamcinolone acetonide (ocular)B3
turoctocog alfaB2
ublituximabC
velmanase alfaD
vonicog alfaB2
vutrisiranD
zilucoplanD
apadamtase alfa / cinaxadamtase alfaB1
seladelparB1

The following database entries have been amended:

MedicineSafety StatementClassification 1Classification 2Classification 3
anacaulase-bcdb From "Dermatology" to "Drugs Used in Dermatology"From "Topical debridement drug" to "Topical"Removed "Proteolytic enzyme enriched in bromelain"
belantamab mafodotinFrom "Based on the mechanism of action of the cytotoxic component monomethyl auristatin F, belantamab mafodotin can cause embryo-fetal harm when administered to a pregnant woman. The cytotoxic component kills rapidly dividing cells, which would affect a developing embryo. There is also a potential risk of heritable changes via aneuploidy in female germ cells" to "Based on its mechanism of action, belantamab mafodotin may cause embryofetal harm (embryotoxicity and teratogenicity) when administered to a pregnant woman"   
vanzacaftor / tezacaftor / deutivacaftor  From "Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators" to "Inhalational agents" 
From "delgocitinib" to "delgocitinib (dermal)" From "Immunomodulating" to "Allergy and Immune System"From "Topical kinase inhibitor for chronic hand eczema" to "Immunomodifiers" 
baricitinib From "Musculoskeletal System" to "Allergy and Immune System"From "Antirheumatoid agents" to "Immunomodifiers" 
Topics

Related content